WWM
NPCE icon

Western Wealth Management’s Neuropace NPCE Stock Holding History

Western Wealth Management’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$365K Hold
22,950
– – 0.01% 766
2026
Q1 		$302K Hold
22,950
– – 0.01% 797
2025
Q4 		$354K Sell
22,950
-50
-0.2% -$669 0.02% 612
2025
Q3 		$237K Buy
+23,000
New +$217K 0.01% 683

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Western Wealth Management's NPCE Position: Q2 2026 in Review

Western Wealth Management held its Neuropace (NPCE) position steady in Q2 2026 at 22,950 shares worth $365K. The position accounts for 0.01% of the portfolio, ranked #766.

Western Wealth Management first reported a position in NPCE in Q3 2025 and has held it in 4 quarters since. 113 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • Western Wealth Management held 22,950 shares of Neuropace worth $365K as of Q2 2026.
  • Western Wealth Management left its Neuropace share count unchanged in Q2 2026.
  • Neuropace made up 0.01% of Western Wealth Management's portfolio in Q2 2026, its #766 holding.
  • Western Wealth Management first reported a position in Neuropace in Q3 2025 and has held it in 4 quarters since.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Western Wealth Management's 13F filing for Q2 2026, filed 14 Aug 2026.